| Field | Sense | Antisense |
| siRNA chemical modification | 2-Deoxyribonucleotide* Inverted thymidine | 2-Deoxyribonucleotide* Inverted thymidine |
| siRNA modification types | 2 | 2 |
| Overall number of modifications | 2 | 2 |
| Position of modifications | 20 * 21 | 20 * 21 |
| Modification on sugar or base or phosphate | Sugar | Sugar |
| SMILES (Click to view structure & nomenclature) |
OCC1OCCC1O CC1=CN(C2CC(OP([O-])(=O)OC3C(O)COC3CO)C(CO)O2)C(=O)NC1=O |
OCC1OCCC1O CC1=CN(C2CC(OP([O-])(=O)OC3C(O)COC3CO)C(CO)O2)C(=O)NC1=O |
| siRNA Sequence | UCCUACAGCACAACAAAUGUG | CAUUUGUUGUGCUGUAGGAAG |
| siRNA length base-pair | 21 | 21 |
| siRNA name in paper | siVEGF-idT | siVEGF-idT |
| Biological activity | 12 percent target mRNA inhibition | |
| Experiment used to check activity | Real-time PCR | |
| Melting temperature (oC) | NA | |
| Target gene | vascular endothelial growth factor (VEGF) gene | |
| siRNA concentration | 1 uM | |
| Cell or Organism used | HeLa cells | |
| Transfection method | Absence of Lipofectamine 2000 | |
| Duration after transfection | 48 Hours | |
| Article title | Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity |
|
| Reference | 21985606 | |